ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.
Stocks · News reference
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ArriVent BioPharma shares are trading lower after the company announced its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion-mutant NSCLC failed to meet its primary endpoint of progression-free survival.
Dow Jumps 200 Points; US Trade Deficit Widens In August
U.S. stocks rose Tuesday, led by Nasdaq and S&P 500, while August’s trade deficit hit $105.6B. Utilities gained; energy and oil fell.
AMD, Constellation Energy, Marvell Technology, Option Care Health and FuelCell Energy: Why These 5 Stocks Are on Investors' Radars Today
AMD, CEG, MRVL, OPCH, FCEL were among the stocks seen trending on Tuesday, Oct. 6, 2026.
FuelCell Energy Stock Gains 14% Today — Here's Why
FuelCell stock rose 14% as Google’s nuclear deal highlighted soaring AI power demand.
Why Constellation Energy Rallied Today
Constellation Energy stock surged 12.31% after signing a comprehensive power deal with Alphabet. The agreement includes a 20-year, 890-MW power purchase agreement and a 15-year, 2,700-MW PPA to supply nuclear power to Alphabet's AI data centers in the PJM grid region. Constellation will invest $4.3 billion to expand nuclear capacity, while Alphabet will use Google Cloud's Gemini Enterprise to help optimize power production efficiency.